We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+23.47%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.49B
AUM Growth
+$497M
Cap. Flow
+$426M
Cap. Flow %
12.21%
Top 10 Hldgs %
38.36%
Holding
80
New
20
Increased
14
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$161M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$139M
3
APLS
Apellis Pharmaceuticals
APLS
+$63.7M
4
DYN icon
Dyne Therapeutics
DYN
+$57.8M
5
NTLA icon
Intellia Therapeutics
NTLA
+$54.5M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$52.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48.2M
3
RAPT
RAPT Therapeutics
RAPT
+$44.6M
4
ACLX
Arcellx
ACLX
+$40.2M
5
ANAB icon
AnaptysBio
ANAB
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
51
Scholar Rock
SRRK
$6.01B
$12.1M 0.35%
680,000
-331,829
-33% -$5.22M
ANAB icon
52
AnaptysBio
ANAB
$1.6B
$11.9M 0.34%
529,452
-1,507,538
-74% -$35.7M
RGLS
53
DELISTED
Regulus Therapeutics
RGLS
$9.41M 0.27%
+3,266,566
New +$5.33M
ANRO icon
54
Alto Neuroscience
ANRO
$1.21B
$9.21M 0.26%
+600,000
New +$9.39M
RARE icon
55
Ultragenyx Pharmaceutical
RARE
$1.27B
$7.83M 0.22%
+167,784
New +$7.91M
ZURA icon
56
Zura Bio
ZURA
$462M
$6.48M 0.19%
2,523,000
– –
ALLK
57
DELISTED
Allakos
ALLK
$6.3M 0.18%
5,000,000
+2,489,264
+99% +$3.87M
ALGS icon
58
Aligos Therapeutics
ALGS
$31M
$5.98M 0.17%
244,111
– –
RLMD icon
59
Relmada Therapeutics
RLMD
$454M
$5.77M 0.17%
1,240,034
-804,473
-39% -$3.88M
VIGL
60
DELISTED
Vigil Neuroscience
VIGL
$5.44M 0.16%
1,594,931
– –
MGX icon
61
Metagenomi Therapeutics
MGX
$43.8M
$4.92M 0.14%
+466,232
New +$5.36M
SYRS
62
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.43M 0.13%
828,485
– –
MRSN
63
DELISTED
Mersana Therapeutics
MRSN
$2.6M 0.07%
+23,187
New +$2.31M
PRME icon
64
Prime Medicine
PRME
$559M
$2.13M 0.06%
+303,716
New +$2.3M
COGT icon
65
Cogent Biosciences
COGT
$5.73B
$2.12M 0.06%
+316,000
New +$1.95M
GPCR icon
66
Structure Therapeutics
GPCR
$2.63B
$1.72M 0.05%
40,137
-259,863
-87% -$11M
ACLX
67
DELISTED
Arcellx
ACLX
– –
-725,145
Closed -$40.2M
AGIO icon
68
Agios Pharmaceuticals
AGIO
$2.01B
– –
-1,062,881
Closed -$23.7M
CYTK icon
69
CALL
Cytokinetics
CYTK
$9.75B
– –
-1,347,300
Closed -$112M
CYTK icon
70
Cytokinetics
CYTK
$9.75B
– –
-288,949
Closed -$24.1M
EWTX icon
71
Edgewise Therapeutics
EWTX
$4.84B
– –
-2,537,176
Closed -$27.8M
GHRS icon
72
GH Research
GHRS
$1.9B
– –
-499,400
Closed -$2.9M
JAZZ icon
73
Jazz Pharmaceuticals
JAZZ
$15.8B
– –
-48,280
Closed -$5.94M
PRTA icon
74
CALL
Prothena Corp
PRTA
$426M
– –
-500,000
Closed -$18.2M
PRTA icon
75
PUT
Prothena Corp
PRTA
$426M
– –
-250,000
Closed -$9.09M
1 2
3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Deep Track Capital held 80 positions worth $3.49B, up 17% from $2.99B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deep Track Capital deployed $426M of net new capital in Q1 2024, opening 20 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 550,000 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AnaptysBio, an estimated $35.7M trimmed.

  • Deep Track Capital's largest Q1 2024 buy was Amgen: 550,000 shares worth $156M.
  • Deep Track Capital added most to Dyne Therapeutics in Q1 2024, an estimated $57.8M increase.
  • Deep Track Capital's biggest Q1 2024 reduction was AnaptysBio, cutting an estimated $35.7M.
  • Deep Track Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $52.8M.
  • Deep Track Capital's ten largest holdings make up 38% of its $3.49B portfolio in Q1 2024.
  • Deep Track Capital opened 20 new positions and closed 14 in Q1 2024.
  • Deep Track Capital's portfolio value rose 17% quarter-over-quarter to $3.49B.

Based on Deep Track Capital's 13F filing for Q1 2024, filed 15 May 2024.